2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• 化学式: C₂₂H₂₉N₃O₆S
• 分子量: 463.5
• InChiKey: ZEMIJUDPLILVNQ-JTOWHCCKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  溴巴坦 、 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 生成 (2S,5R,6R)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
  参考文献：
  名称：

  VON, DAEHNE, W.

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydrochloride 、 碳酸氢钠 以 乙醚 为溶剂， 生成 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
  参考文献：
  名称：

  Crystalline pivaloyloxymethyl d(-)-.alpha.-aminobenzylpenicillinate

  摘要：

  本发明涉及一种新的改进形式的戊二酰氧甲基D（-）-α-氨基苯青霉酸苄酯，即晶体形式I，其化学式为##SPC1##以及制备该晶体戊二酰氧甲基D（-）-α-氨基苯青霉酸苄酯的方法和含有该晶体戊二酰氧甲基D（-）-α-氨基苯青霉酸苄酯的药物制剂。晶体戊二酰氧甲基D（-）-α-氨基苯青霉酸苄酯无苦味，只在水中微溶，稳定易吸收。

  公开号：

  US03956279A1

文献信息

• Process for the preparation of pure 6-.beta.-halopenicillanic acids and
  申请人：Leo Pharmaceuticals

  公开号：US04672114A1

  公开（公告）日：1987-06-09

  This invention relates to penicillanic acid derivatives of the formula I ##STR1## in which X stands for chlorine, bromine or iodine, to pharmaceutically acceptable, non-toxic salts of the compounds of formula I, to pharmaceutically acceptable, easily hydrolyzable esters thereof, including salts of such esters, to pharmaceutical compositions containing the compounds of the invention and dosage units thereof, to methods for the preparation of the compounds of the invention, and to methods of using the said new compounds in the human and veterinary therapy. The 6.beta.-halopenicillanic acids of formula I are potent inhibitors of .beta.-lactamases from a variety of gram-positive and gram-negative bacteria, making the 6.beta.-halopenicillanic acids as well as their salts and easily hydrolyzable esters valuable in human and veterinary medicine.

  本发明涉及公式I的青霉烷酸衍生物，其中X代表氯、溴或碘，以及该公式I化合物的药学上可接受的、无毒的盐，其易水解的药学上可接受的酯，包括这种酯的盐，含有本发明化合物和剂量单位的制药组合物，制备本发明化合物的方法，以及在人类和兽医治疗中使用这些新化合物的方法。公式I的6β-卤代青霉烷酸是各种革兰氏阳性和阴性细菌β-内酰胺酶的强效抑制剂，使得6β-卤代青霉烷酸及其盐和易水解的酯在人类和兽医学中具有重要价值。
• Derivatives of penicillanic acid
  申请人：Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik

  公开号：US04446144A1

  公开（公告）日：1984-05-01

  This invention relates to penicillanic acid derivatives of the formula I ##STR1## in which X stands for chlorine, bromine or iodine, to pharmaceutically acceptable, non-toxic salts of the compounds of formula I, to pharmaceutically acceptable, easily hydrolyzable esters thereof, including salts of such esters, to pharmaceutical compositions containing the compounds of the invention and dosage units thereof, to methods for the preparation of the compounds of the invention, and to methods of using the said new compounds in the human and veterinary therapy. The 6.beta.-halopenicillanic acids of formula I are potent inhibitors of .beta.-lactamases from a variety of gram-positive and gram-negative bacteria, making the 6.beta.-halopenicillanic acids as well as their salts and easily hydrolyzable esters valuable in human and veterinary medicine.

  本发明涉及式I的青霉烷酸衍生物##STR1## 其中X代表氯、溴或碘，以及该式化合物的药学上可接受、无毒的盐、易水解酯类及其盐的药学上可接受的制剂，包括含有本发明化合物及其剂量单位的药物组合物，制备本发明化合物的方法以及在人类和兽医治疗中使用这些新化合物的方法。式I的6β-卤代青霉烷酸是各种革兰氏阳性和阴性细菌的β-内酰胺酶的有效抑制剂，使得6β-卤代青霉烷酸及其盐和易水解酯类在人类和兽医医学中具有重要的价值。
• Pharmaceutically-acceptable amine salts of 6-.beta.-halopenicillanic
  申请人：Leo Pharmaceutical Products

  公开号：US04594246A1

  公开（公告）日：1986-06-10

  This invention relates to penicillanic acid derviatives of the formula I ##STR1## in which X stands for chlorine, bromine or iodine, to pharmaceutically acceptable, non-toxic salts of the compounds of formula I, to pharmaceutically acceptable, easily hydrolyzable esters thereof, including salts of such esters, to pharmaceutical compositions containing the compounds of the invention and dosage units thereof, to methods for the preparation of the compounds of the invention, and to methods of using the said new compounds in the human and veterinary therapy. The 6.beta.-halopenicillanic acids of formula I are potent inhibitors of .beta.-lactamases from a variety of gram-positive and gram-negative bacteria, making the 6.beta.-halopenicillanic acids as well as their salts and easily hydrolyzable esters valuable in human and veterinary medicine.

  本发明涉及公式I的青霉烷酸衍生物，其中X代表氯、溴或碘，以及公式I化合物的药学上可接受的、无毒的盐，其易水解的酯物，包括这些酯物的盐，含有本发明化合物的制药组合物以及其剂量单位，制备本发明化合物的方法，以及在人类和兽医治疗中使用这些新化合物的方法。公式I的6β-卤代青霉烷酸是各种革兰氏阳性和阴性细菌β-内酰胺酶的强效抑制剂，使得6β-卤代青霉烷酸及其盐和易水解的酯物在人类和兽医学中有价值。